pre- vs post- adjuvant anti-PD1 treatment in available tumor (N=24) samples. B. OS according to TMEHigh and non-TMEHigh (TMELow + TMEMed) subtypes who received adjuvant anti-PD1 therapy in the Zhao cohort (N=15 patients). C. Relative boxplots indicating the proportion of TMELow, TMEMed and TMEHigh patients before administration of anti-PD1 treatment (left) and after anti-PD1 treatment (right) in available tumor and blood samples. D. Partition around medoids (PAM) clustering of the PVSRIPO cohort19Desjardins A. Gromeier M. Herndon J.E. Beaubier N. Bolognesi D.P. Friedman A.H. et al.Recurrent Glioblastoma Treated with Recombinant Poliovirus.New England Journal of Medicine. July 12, 2018; 379: 150-161CrossrefPubMedScopus (0)Google Scholar with available RNA-seq data (N=12), based on the cellular TME composition described by GBM-MCP-counter scores reveal 3 subtypes; TMElow, TME med and TME high. E. OS according to TMELow and TMEMed and TMEHigh subtypes who received PVSRIPO therapy in the PVSRIPO cohort19Desjardins A. Gromeier M. Herndon J.E. Beaubier N. Bolognesi D.P. Friedman A.H. et al.Recurrent Glioblastoma Treated with Recombinant Poliovirus.New England Journal of Medicine. July 12, 2018; 379: 150-161CrossrefPubMedScopus (0)Google Scholar. Statistical test: Wilcoxon signed rank test. Kaplan Meier analysis; P value of log-ranked test. *P<0.05 ** P<0.01. Credit: Annals of Oncology (2022). DOI: 10.1016/j.annonc.2022.11.008">
趋势改进操作系统和增加了时差的反应率高患者辅助治疗后pembrolizumab或PVSRIPO。答:时间在赵数据集组成18赵J,陈AX,加特雷尔RD,西尔弗曼,Aparicio L,楚T, et al。免疫和基因相关的响应anti-PD-1在胶质母细胞瘤免疫治疗。Nat地中海。3月11日,2019,25 (3):462 - 469。可以在http://www.nature.com/articles/s41591 - 019 - 0349 - ygoogle学者前和后可用辅助anti-PD1治疗肿瘤(N = 24)样本。操作系统根据时间高和non-TME高(时间低+时间地中海)亚型接受辅助治疗anti-PD1赵组(N = 15例)。箱线图显示的比例相对时间低,开心的地中海和时间高病人管理anti-PD1治疗前(左)和anti-PD1治疗后(右)在肿瘤和血液样本。d .分区在medoids PVSRIPO队列(PAM)集群19德斯贾丁斯a Gromeier m·赫恩登J.E. Beaubier n Bolognesi D.P.弗里德曼A.H. et al.Recurrent胶质母细胞瘤治疗脊髓灰质炎病毒重组。新英格兰医学杂志》上。2018年7月12日;379:150 - 161 - crossrefpubmedscopus(0)谷歌学者RNA-seq可用数据(N = 12),基于细胞时间成分被GBM-MCP-counter分数显示3亚型;开心的低,时间地中海和时间高。e .操作系统根据时间低和时间地中海和时间高亚型接受PVSRIPO疗法PVSRIPO队列19德斯贾丁斯a Gromeier m·赫恩登J.E. Beaubier n Bolognesi D.P.弗里德曼A.H. et al.Recurrent胶质母细胞瘤治疗脊髓灰质炎病毒重组。新英格兰医学杂志》上。2018年7月12日;379:150 - 161 - crossrefpubmedscopus(0)谷歌学者。统计检验:魏克森讯号等级测试。卡普兰Meier分析;P log-ranked测试的价值。* P < 0.05 * * P < 0.01。信贷:《肿瘤学(2022)。DOI: 10.1016 / j.annonc.2022.11.008
